[
  {
    "id": "NCT04613596",
    "title": "A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation",
    "phase": "PHASE2, PHASE3",
    "description": "No description provided.",
    "inclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Phase 2: Histologically confirmed diagnosis of unresectable or metastatic NSCLC with KRAS G12C mutation and any PD-L1 TPS",
      "* Phase 3: Histologically confirmed diagnosis of unresectable or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \\>=50%",
      "* Phase 3: Presence of evaluable or measurable disease per RECIST",
      "* Phase 3: CNS Inclusion - Based on screening brain imaging, patients must have one of the following:",
      "",
      "  1. No evidence of brain metastases",
      "  2. Untreated brain metastases not needing immediate local therapy",
      "  3. Previously treated brain metastases not needing immediate local therapy",
      "",
      "Exclusion Criteria:",
      "",
      "* Phase 2 and Phase 3: Prior systemic treatment for locally advanced or metastatic NSCLC including chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting KRAS G12C mutation (e.g., AMG 510).",
      "* Phase 2: Active brain metastases",
      "* Phase 3: Patients with known central nervous system (CNS) lesions must not have any of the following:",
      "",
      "  1. Any untreated brain lesions \\> 1.0 cm in size",
      "  2. Any brainstem lesions",
      "  3. Ongoing use of systemic corticosteroids for control of symptoms of brain lesions at a total daily dose of \\> 10 mg of prednisone (or equivalent) prior to randomization.",
      "  4. Have poorly controlled (\\> 1/week) generalized or complex partial seizures, or manifest neurologic progression due to brain lesions notwithstanding CNS-directed therapy",
      "* Phase 3: Radiation to the lung \\> 30 Gy within 6 months prior to the first dose of study treatment"
    ],
    "exclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Phase 2: Histologically confirmed diagnosis of unresectable or metastatic NSCLC with KRAS G12C mutation and any PD-L1 TPS",
      "* Phase 3: Histologically confirmed diagnosis of unresectable or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \\>=50%",
      "* Phase 3: Presence of evaluable or measurable disease per RECIST",
      "* Phase 3: CNS Inclusion - Based on screening brain imaging, patients must have one of the following:",
      "",
      "  1. No evidence of brain metastases",
      "  2. Untreated brain metastases not needing immediate local therapy",
      "  3. Previously treated brain metastases not needing immediate local therapy",
      "",
      "Exclusion Criteria:",
      "",
      "* Phase 2 and Phase 3: Prior systemic treatment for locally advanced or metastatic NSCLC including chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting KRAS G12C mutation (e.g., AMG 510).",
      "* Phase 2: Active brain metastases",
      "* Phase 3: Patients with known central nervous system (CNS) lesions must not have any of the following:",
      "",
      "  1. Any untreated brain lesions \\> 1.0 cm in size",
      "  2. Any brainstem lesions",
      "  3. Ongoing use of systemic corticosteroids for control of symptoms of brain lesions at a total daily dose of \\> 10 mg of prednisone (or equivalent) prior to randomization.",
      "  4. Have poorly controlled (\\> 1/week) generalized or complex partial seizures, or manifest neurologic progression due to brain lesions notwithstanding CNS-directed therapy",
      "* Phase 3: Radiation to the lung \\> 30 Gy within 6 months prior to the first dose of study treatment"
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "Not specified",
    "status": "RECRUITING",
    "start_date": "2020-12-02",
    "completion_date": "2029-10-31",
    "sponsor": "Unknown",
    "last_updated": "2025-05-06"
  },
  {
    "id": "NCT05224141",
    "title": "A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer",
    "phase": "PHASE3",
    "description": "No description provided.",
    "inclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Has histologically or cytologically confirmed diagnosis of ES-SCLC in need of first-line therapy",
      "* Has ES-SCLC defined as Stage IV (T any, N any, M1a/b/c) by the American Joint Committee on Cancer, Eighth Edition or T3-T4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan",
      "* Males agree to use contraception, refrain from donating sperm, and abstain from heterosexual intercourse",
      "* Females are not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP) or is a WOCBP who uses a highly effective contraceptive method, or is abstinent from heterosexual intercourse",
      "* Has measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1",
      "* Has a predicted life expectancy of \\>3 months",
      "",
      "Exclusion Criteria:",
      "",
      "* Is considered a poor medical risk due to a serious, uncontrolled medical disorder or non-malignant systemic disease",
      "* Has received prior treatment for Small Cell Lung Cancer (SCLC)",
      "* Is expected to require any other form of antineoplastic therapy for SCLC while on study",
      "* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention",
      "* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration",
      "* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication",
      "* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years",
      "* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis",
      "* Has a history of severe hypersensitivity reaction (≥Grade 3) to any study intervention and/or any of its excipients",
      "* Has an active autoimmune disease that has required systemic treatment in past 2 years",
      "* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease",
      "* Has a known history of, or active, neurologic paraneoplastic syndrome",
      "* Has an active infection requiring systemic therapy",
      "* Has a known history of human immunodeficiency virus (HIV) infection",
      "* Has a known history of Hepatitis B or known active Hepatitis C virus infection",
      "* Has had an allogenic tissue/solid organ transplant",
      "* Has had major surgery within prior 3 weeks or has not recovered adequately from toxicity and/or complications from an intervention prior to receiving the first dose of study intervention",
      "* Has symptomatic ascites or pleural effusion"
    ],
    "exclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Has histologically or cytologically confirmed diagnosis of ES-SCLC in need of first-line therapy",
      "* Has ES-SCLC defined as Stage IV (T any, N any, M1a/b/c) by the American Joint Committee on Cancer, Eighth Edition or T3-T4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan",
      "* Males agree to use contraception, refrain from donating sperm, and abstain from heterosexual intercourse",
      "* Females are not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP) or is a WOCBP who uses a highly effective contraceptive method, or is abstinent from heterosexual intercourse",
      "* Has measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1",
      "* Has a predicted life expectancy of \\>3 months",
      "",
      "Exclusion Criteria:",
      "",
      "* Is considered a poor medical risk due to a serious, uncontrolled medical disorder or non-malignant systemic disease",
      "* Has received prior treatment for Small Cell Lung Cancer (SCLC)",
      "* Is expected to require any other form of antineoplastic therapy for SCLC while on study",
      "* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention",
      "* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration",
      "* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication",
      "* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years",
      "* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis",
      "* Has a history of severe hypersensitivity reaction (≥Grade 3) to any study intervention and/or any of its excipients",
      "* Has an active autoimmune disease that has required systemic treatment in past 2 years",
      "* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease",
      "* Has a known history of, or active, neurologic paraneoplastic syndrome",
      "* Has an active infection requiring systemic therapy",
      "* Has a known history of human immunodeficiency virus (HIV) infection",
      "* Has a known history of Hepatitis B or known active Hepatitis C virus infection",
      "* Has had an allogenic tissue/solid organ transplant",
      "* Has had major surgery within prior 3 weeks or has not recovered adequately from toxicity and/or complications from an intervention prior to receiving the first dose of study intervention",
      "* Has symptomatic ascites or pleural effusion"
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "Not specified",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2022-03-24",
    "completion_date": "2027-06-07",
    "sponsor": "Unknown",
    "last_updated": "2025-02-03"
  },
  {
    "id": "NCT05261399",
    "title": "A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).",
    "phase": "PHASE3",
    "description": "No description provided.",
    "inclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Provision of signed and dated written ICF prior to any mandatory and non-mandatory study-specific procedures, sampling and analyses.",
      "* Participant must be ≥18 years (≥ 19 years of age in South Korea) at the time of signing the informed consent. All genders are permitted.",
      "* Histologically or cytologically confirmed locally advanced or metastatic NSCLC which is not amenable to curative therapy.",
      "* Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M.",
      "* Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy.",
      "* Mandatory provision of FFPE tumour tissue.",
      "* MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment.",
      "* Measurable disease as defined by RECIST 1.1.",
      "* Adequate haematological, liver, renal and cardiac functions, and coagulation parameters.",
      "* ECOG performance status of 0 or 1.",
      "",
      "Exclusion Criteria:",
      "",
      "* Predominant squamous NSCLC, and small cell lung cancer.",
      "* Prior or current treatment with a third-generation EGFR-TKI other than Osimertinib.",
      "* Prior or current treatment with savolitinib or another MET inhibitors.",
      "* Spinal cord compression or brain metastases, unless asymptomatic and are stable.",
      "* History or active leptomeningeal carcinomatosis.",
      "* Unresolved toxicities from any prior therapy greater than CTCAE Grade 1 and prior platinum-therapy related Grade 2 neuropathies with the exception of alopecia and haemoglobin ≥ 9.0 g/dL.",
      "* Active/unstable cardiac diseases currently or within the last 6 months, clinically significant ECG abnormalities, and/or factors/medications that may affect QTc intervals.",
      "* History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement.",
      "* Known serious active infection including, but not limited to, tuberculosis, or HIV, HBV or HCV or gastrointestinal disease.",
      "* Receipt of live attenuated vaccine (including against COVID-19) within 30 days prior to the first dose of study intervention.",
      "* Past medical history of ILD, drug-induced ILD, radiation pneumonitis, which required steroid treatment, or any evidence of clinically active ILD.",
      "* Participants currently receiving medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP)3A4 or strong inhibitors of CYP1A2."
    ],
    "exclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Provision of signed and dated written ICF prior to any mandatory and non-mandatory study-specific procedures, sampling and analyses.",
      "* Participant must be ≥18 years (≥ 19 years of age in South Korea) at the time of signing the informed consent. All genders are permitted.",
      "* Histologically or cytologically confirmed locally advanced or metastatic NSCLC which is not amenable to curative therapy.",
      "* Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M.",
      "* Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy.",
      "* Mandatory provision of FFPE tumour tissue.",
      "* MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment.",
      "* Measurable disease as defined by RECIST 1.1.",
      "* Adequate haematological, liver, renal and cardiac functions, and coagulation parameters.",
      "* ECOG performance status of 0 or 1.",
      "",
      "Exclusion Criteria:",
      "",
      "* Predominant squamous NSCLC, and small cell lung cancer.",
      "* Prior or current treatment with a third-generation EGFR-TKI other than Osimertinib.",
      "* Prior or current treatment with savolitinib or another MET inhibitors.",
      "* Spinal cord compression or brain metastases, unless asymptomatic and are stable.",
      "* History or active leptomeningeal carcinomatosis.",
      "* Unresolved toxicities from any prior therapy greater than CTCAE Grade 1 and prior platinum-therapy related Grade 2 neuropathies with the exception of alopecia and haemoglobin ≥ 9.0 g/dL.",
      "* Active/unstable cardiac diseases currently or within the last 6 months, clinically significant ECG abnormalities, and/or factors/medications that may affect QTc intervals.",
      "* History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement.",
      "* Known serious active infection including, but not limited to, tuberculosis, or HIV, HBV or HCV or gastrointestinal disease.",
      "* Receipt of live attenuated vaccine (including against COVID-19) within 30 days prior to the first dose of study intervention.",
      "* Past medical history of ILD, drug-induced ILD, radiation pneumonitis, which required steroid treatment, or any evidence of clinically active ILD.",
      "* Participants currently receiving medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP)3A4 or strong inhibitors of CYP1A2."
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "130 Years",
    "status": "RECRUITING",
    "start_date": "2022-08-03",
    "completion_date": "2026-12-17",
    "sponsor": "Unknown",
    "last_updated": "2025-01-10"
  },
  {
    "id": "NCT05298423",
    "title": "Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC",
    "phase": "PHASE3",
    "description": "No description provided.",
    "inclusion_criteria": [
      "The main inclusion and exclusion criteria include but are not limited to the following:",
      "",
      "Inclusion Criteria",
      "",
      "* Has pathologically (histologically or cytologically) confirmed diagnosis of NSCLC.",
      "* Has Stage IIIA, IIIB, or IIIC NSCLC by American Joint Committee on Cancer Version 8",
      "* Is determined to have unresectable, Stage III NSCLC as documented by a multidisciplinary tumor board or by the treating physician in consultation with a thoracic surgeon",
      "* Has no evidence of metastatic disease, indicating Stage IV NSCLC, in whole-body fluorodeoxyglucose (FDG)-positron emission tomography (PET) or FDG-PET/ computed tomography (CT) and CT or magnetic resonance imaging (MRI) scans of diagnostic quality of chest, abdomen, pelvis and brain",
      "* Has measurable disease as defined by RECIST 1.1, with at least 1 lesion being appropriate for selection as a target lesion, as determined by local site investigator/radiology review",
      "* Has not received prior treatment (chemotherapy, targeted therapy, or radiotherapy) for their Stage III NSCLC",
      "* Has provided tumor tissue sample (tissue biopsy \\[core, incisional, or excisional\\])",
      "* Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 assessed within 7 days prior to the first administration of study intervention",
      "* Has a life expectancy of at least 6 months",
      "",
      "Exclusion Criteria",
      "",
      "* Has small cell lung cancer (SCLC) or tumors with the presence of small cell elements. Mixed squamous/nonsquamous tumors are eligible",
      "* Has received prior radiotherapy to the thorax, including radiotherapy to the esophagus, mediastinum, or for breast cancer",
      "* Has received major surgery (with the exception of replacement of vascular access) within 4 weeks before randomization. If the participant had a major operation, the participant must have recovered adequately from the procedure and/or any complications from the operation before starting study intervention",
      "* Is expected to require any other form of antineoplastic therapy, while on study",
      "* Has received colony-stimulating factors (e.g., Granulocyte Colony-Stimulating Factor \\[G-CSF\\], Granulocyte Macrophage Colony-Stimulating Factor \\[GM-CSF\\], or recombinant erythropoietin) within 28 days prior to the first dose of study intervention",
      "* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention",
      "* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention",
      "* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication",
      "* Has a known additional malignancy that is progressing or has required active treatment within the past 5 years",
      "* Has an active autoimmune disease that has required systemic treatment in past 2 years",
      "* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease",
      "* Has an active infection requiring systemic therapy",
      "* Has a known history of human immunodeficiency virus (HIV) infection",
      "* Has a known history of Hepatitis B (defined as hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV ribonucleic acid \\[RNA\\] qualitative is detected) infection",
      "* Has had an allogenic tissue/solid organ transplant",
      "",
      "Pemetrexed-specific Criteria:",
      "",
      "* Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 grams per day, for at least 2 days (5 days for long-acting agents \\[for example, piroxicam\\]) before, during, and for at least 2 days after administration of pemetrexed",
      "* Is unable/unwilling to take folic acid, vitamin B12, and dexamethasone"
    ],
    "exclusion_criteria": [
      "The main inclusion and exclusion criteria include but are not limited to the following:",
      "",
      "Inclusion Criteria",
      "",
      "* Has pathologically (histologically or cytologically) confirmed diagnosis of NSCLC.",
      "* Has Stage IIIA, IIIB, or IIIC NSCLC by American Joint Committee on Cancer Version 8",
      "* Is determined to have unresectable, Stage III NSCLC as documented by a multidisciplinary tumor board or by the treating physician in consultation with a thoracic surgeon",
      "* Has no evidence of metastatic disease, indicating Stage IV NSCLC, in whole-body fluorodeoxyglucose (FDG)-positron emission tomography (PET) or FDG-PET/ computed tomography (CT) and CT or magnetic resonance imaging (MRI) scans of diagnostic quality of chest, abdomen, pelvis and brain",
      "* Has measurable disease as defined by RECIST 1.1, with at least 1 lesion being appropriate for selection as a target lesion, as determined by local site investigator/radiology review",
      "* Has not received prior treatment (chemotherapy, targeted therapy, or radiotherapy) for their Stage III NSCLC",
      "* Has provided tumor tissue sample (tissue biopsy \\[core, incisional, or excisional\\])",
      "* Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 assessed within 7 days prior to the first administration of study intervention",
      "* Has a life expectancy of at least 6 months",
      "",
      "Exclusion Criteria",
      "",
      "* Has small cell lung cancer (SCLC) or tumors with the presence of small cell elements. Mixed squamous/nonsquamous tumors are eligible",
      "* Has received prior radiotherapy to the thorax, including radiotherapy to the esophagus, mediastinum, or for breast cancer",
      "* Has received major surgery (with the exception of replacement of vascular access) within 4 weeks before randomization. If the participant had a major operation, the participant must have recovered adequately from the procedure and/or any complications from the operation before starting study intervention",
      "* Is expected to require any other form of antineoplastic therapy, while on study",
      "* Has received colony-stimulating factors (e.g., Granulocyte Colony-Stimulating Factor \\[G-CSF\\], Granulocyte Macrophage Colony-Stimulating Factor \\[GM-CSF\\], or recombinant erythropoietin) within 28 days prior to the first dose of study intervention",
      "* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention",
      "* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention",
      "* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication",
      "* Has a known additional malignancy that is progressing or has required active treatment within the past 5 years",
      "* Has an active autoimmune disease that has required systemic treatment in past 2 years",
      "* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease",
      "* Has an active infection requiring systemic therapy",
      "* Has a known history of human immunodeficiency virus (HIV) infection",
      "* Has a known history of Hepatitis B (defined as hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV ribonucleic acid \\[RNA\\] qualitative is detected) infection",
      "* Has had an allogenic tissue/solid organ transplant",
      "",
      "Pemetrexed-specific Criteria:",
      "",
      "* Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 grams per day, for at least 2 days (5 days for long-acting agents \\[for example, piroxicam\\]) before, during, and for at least 2 days after administration of pemetrexed",
      "* Is unable/unwilling to take folic acid, vitamin B12, and dexamethasone"
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "Not specified",
    "status": "ACTIVE_NOT_RECRUITING",
    "start_date": "2022-05-03",
    "completion_date": "2026-08-19",
    "sponsor": "Unknown",
    "last_updated": "2025-03-28"
  },
  {
    "id": "NCT06312137",
    "title": "A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery",
    "phase": "PHASE3",
    "description": "No description provided.",
    "inclusion_criteria": [
      "The key inclusion and exclusion criteria include but are not limited to the following:",
      "",
      "Inclusion Criteria:",
      "",
      "* Has histological or cytological confirmation of squamous or nonsquamous non-small cell lung cancer (NSCLC), resectable clinical Stage II, IIIA or IIIB (with nodal involvement \\[N2\\]) per AJCC eighth edition guidelines",
      "* Has confirmation that either epidermal growth factor receptor (EGFR)-directed or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated as primary therapy",
      "* Is able to undergo surgery based on opinion of investigator after consultation with surgeon",
      "* Is able to receive neoadjuvant pembrolizumab and platinum-based doublet chemotherapy",
      "* Applies to screening for the adjuvant period only, before randomization: Has not achieved pathological complete response (pCR) at surgery by local review of pathology.",
      "* Applies to screening for the adjuvant period only, before randomization: Tumor tissue sample from surgical resection has been provided for determination of programmed cell death ligand 1 (PD-L1) and trophoblast cell surface antigen 2 (TROP2) status by central vendor before randomization into the adjuvant period",
      "* Applies to screening for the adjuvant period only, before randomization: Confirmed to be disease-free based on re-baseline radiological assessment as documented by contrast enhanced chest/abdomen/pelvis computed tomography (CT) (or magnetic resonance imaging (MRI)) within 28 days before randomization",
      "* Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible",
      "* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)",
      "* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load at screening",
      "* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at least 4 weeks before the start of study intervention",
      "",
      "Exclusion Criteria:",
      "",
      "* Has one of the following tumor locations/types:",
      "",
      "  * NSCLC involving the superior sulcus",
      "  * Large cell neuro-endocrine cancer (LCNEC)",
      "  * Sarcomatoid tumor",
      "  * Diagnosis of SCLC or, for mixed tumors, presence of small cell elements",
      "* Has Grade ≥2 peripheral neuropathy",
      "* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing",
      "* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease",
      "* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QT corrected for heart rate by Fridericia's cube root formula (QTcF) interval to \\>480 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention",
      "* Has received prior neoadjuvant therapy for their current NSCLC diagnosis",
      "* Has received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention",
      "* Has received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids",
      "* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed",
      "* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration",
      "* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication",
      "* Has a known additional malignancy that is progressing or has required active treatment within the past 5 years",
      "* Has an active autoimmune disease that has required systemic treatment in the past 2 years",
      "* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease",
      "* Has an active infection requiring systemic therapy",
      "* Is an HIV-infected participant with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease",
      "* Has a concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV deoxyribonucleic acid (DNA)) and Hepatitis C virus (defined as anti-HCV antibody (Ab) positive and detectable HCV ribonucleic acid (RNA)) infection",
      "* Has a history of allogeneic tissue/solid organ transplant",
      "* Has not adequately recovered from major surgery or have ongoing surgical complications",
      "* Severe hypersensitivity (≥Grade 3) to study intervention, any of its excipients, and/or to another biologic therapy"
    ],
    "exclusion_criteria": [
      "The key inclusion and exclusion criteria include but are not limited to the following:",
      "",
      "Inclusion Criteria:",
      "",
      "* Has histological or cytological confirmation of squamous or nonsquamous non-small cell lung cancer (NSCLC), resectable clinical Stage II, IIIA or IIIB (with nodal involvement \\[N2\\]) per AJCC eighth edition guidelines",
      "* Has confirmation that either epidermal growth factor receptor (EGFR)-directed or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated as primary therapy",
      "* Is able to undergo surgery based on opinion of investigator after consultation with surgeon",
      "* Is able to receive neoadjuvant pembrolizumab and platinum-based doublet chemotherapy",
      "* Applies to screening for the adjuvant period only, before randomization: Has not achieved pathological complete response (pCR) at surgery by local review of pathology.",
      "* Applies to screening for the adjuvant period only, before randomization: Tumor tissue sample from surgical resection has been provided for determination of programmed cell death ligand 1 (PD-L1) and trophoblast cell surface antigen 2 (TROP2) status by central vendor before randomization into the adjuvant period",
      "* Applies to screening for the adjuvant period only, before randomization: Confirmed to be disease-free based on re-baseline radiological assessment as documented by contrast enhanced chest/abdomen/pelvis computed tomography (CT) (or magnetic resonance imaging (MRI)) within 28 days before randomization",
      "* Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible",
      "* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)",
      "* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load at screening",
      "* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at least 4 weeks before the start of study intervention",
      "",
      "Exclusion Criteria:",
      "",
      "* Has one of the following tumor locations/types:",
      "",
      "  * NSCLC involving the superior sulcus",
      "  * Large cell neuro-endocrine cancer (LCNEC)",
      "  * Sarcomatoid tumor",
      "  * Diagnosis of SCLC or, for mixed tumors, presence of small cell elements",
      "* Has Grade ≥2 peripheral neuropathy",
      "* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing",
      "* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease",
      "* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QT corrected for heart rate by Fridericia's cube root formula (QTcF) interval to \\>480 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention",
      "* Has received prior neoadjuvant therapy for their current NSCLC diagnosis",
      "* Has received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention",
      "* Has received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids",
      "* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed",
      "* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration",
      "* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication",
      "* Has a known additional malignancy that is progressing or has required active treatment within the past 5 years",
      "* Has an active autoimmune disease that has required systemic treatment in the past 2 years",
      "* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease",
      "* Has an active infection requiring systemic therapy",
      "* Is an HIV-infected participant with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease",
      "* Has a concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV deoxyribonucleic acid (DNA)) and Hepatitis C virus (defined as anti-HCV antibody (Ab) positive and detectable HCV ribonucleic acid (RNA)) infection",
      "* Has a history of allogeneic tissue/solid organ transplant",
      "* Has not adequately recovered from major surgery or have ongoing surgical complications",
      "* Severe hypersensitivity (≥Grade 3) to study intervention, any of its excipients, and/or to another biologic therapy"
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "Not specified",
    "status": "RECRUITING",
    "start_date": "2024-04-03",
    "completion_date": "2034-10-23",
    "sponsor": "Unknown",
    "last_updated": "2025-05-11"
  },
  {
    "id": "NCT06305754",
    "title": "A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors",
    "phase": "PHASE3",
    "description": "No description provided.",
    "inclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Histologically or cytologically confirmed diagnosis of advanced-stage nonsquamous non-small cell lung cancer (NSCLC).",
      "* Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade ≤1 or baseline.",
      "* Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load.",
      "* Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable.",
      "* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.",
      "* Life expectancy of at least 3 months.",
      "",
      "Exclusion Criteria:",
      "",
      "* Predominantly squamous cell histology NSCLC.",
      "* History of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.",
      "* Grade ≥2 peripheral neuropathy.",
      "* History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.",
      "* Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease.",
      "* Uncontrolled, or significant cardiovascular disease or cerebrovascular disease.",
      "* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.",
      "* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.",
      "* Received radiation therapy to the lung that is \\>30 Gray within 6 months of the first dose of study intervention.",
      "* Known active central nervous system metastases and/or carcinomatous meningitis.",
      "* Active infection requiring systemic therapy.",
      "* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.",
      "* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.",
      "* Concurrent active HBV and HCV infection.",
      "* History of allogeneic tissue/solid organ transplant.",
      "* Participants who have not adequately recovered from major surgery or have ongoing surgical complications."
    ],
    "exclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Histologically or cytologically confirmed diagnosis of advanced-stage nonsquamous non-small cell lung cancer (NSCLC).",
      "* Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade ≤1 or baseline.",
      "* Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load.",
      "* Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable.",
      "* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.",
      "* Life expectancy of at least 3 months.",
      "",
      "Exclusion Criteria:",
      "",
      "* Predominantly squamous cell histology NSCLC.",
      "* History of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.",
      "* Grade ≥2 peripheral neuropathy.",
      "* History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.",
      "* Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease.",
      "* Uncontrolled, or significant cardiovascular disease or cerebrovascular disease.",
      "* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.",
      "* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.",
      "* Received radiation therapy to the lung that is \\>30 Gray within 6 months of the first dose of study intervention.",
      "* Known active central nervous system metastases and/or carcinomatous meningitis.",
      "* Active infection requiring systemic therapy.",
      "* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.",
      "* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.",
      "* Concurrent active HBV and HCV infection.",
      "* History of allogeneic tissue/solid organ transplant.",
      "* Participants who have not adequately recovered from major surgery or have ongoing surgical complications."
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "Not specified",
    "status": "RECRUITING",
    "start_date": "2024-06-11",
    "completion_date": "2030-06-14",
    "sponsor": "Unknown",
    "last_updated": "2025-05-16"
  },
  {
    "id": "NCT05920356",
    "title": "A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)",
    "phase": "PHASE3",
    "description": "No description provided.",
    "inclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Histologically or cytologically confirmed diagnosis of nonsquamous stage IV or advanced Stage IIIB or IIIC NSCLC with KRAS p. G12C mutation and negative for PD-L1 expression by central testing or local laboratory testing confirmed through central testing",
      "* No history of systemic anticancer therapy in metastatic/non-curable settings",
      "* Eastern Cooperative Oncology Group (ECOG) ≤ 1",
      "",
      "Exclusion Criteria:",
      "",
      "* Mixed histology NSCLC with either small-cell or large-cell neuroendocrine cell component or predominant squamous cell histology",
      "* Participants with tumors known to harbor molecular alterations for which targeted therapy is locally approved",
      "* Symptomatic (treated or untreated) brain metastases",
      "* Gastrointestinal (GI) tract disease causing the inability to take oral medication",
      "* Myocardial infarction within 6 months of randomization, unstable arrhythmias, or unstable angina",
      "* Prior therapy with a KRAS G12C inhibitor"
    ],
    "exclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Histologically or cytologically confirmed diagnosis of nonsquamous stage IV or advanced Stage IIIB or IIIC NSCLC with KRAS p. G12C mutation and negative for PD-L1 expression by central testing or local laboratory testing confirmed through central testing",
      "* No history of systemic anticancer therapy in metastatic/non-curable settings",
      "* Eastern Cooperative Oncology Group (ECOG) ≤ 1",
      "",
      "Exclusion Criteria:",
      "",
      "* Mixed histology NSCLC with either small-cell or large-cell neuroendocrine cell component or predominant squamous cell histology",
      "* Participants with tumors known to harbor molecular alterations for which targeted therapy is locally approved",
      "* Symptomatic (treated or untreated) brain metastases",
      "* Gastrointestinal (GI) tract disease causing the inability to take oral medication",
      "* Myocardial infarction within 6 months of randomization, unstable arrhythmias, or unstable angina",
      "* Prior therapy with a KRAS G12C inhibitor"
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "100 Years",
    "status": "RECRUITING",
    "start_date": "2023-11-16",
    "completion_date": "2031-06-30",
    "sponsor": "Unknown",
    "last_updated": "2025-05-08"
  },
  {
    "id": "NCT06074588",
    "title": "A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations",
    "phase": "PHASE3",
    "description": "No description provided.",
    "inclusion_criteria": [
      "The main inclusion and exclusion criteria include but are not limited to the following:",
      "",
      "Inclusion Criteria:",
      "",
      "* Histologically- or cytologically-documented advanced (Stage III not eligible for resection or curative radiation) or metastatic non-squamous NSCLC with specific mutations.",
      "* Documentation of locally assessed radiological disease progression while on or after last treatment based on Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1.",
      "* Participants with genome mutations must have received 1 or 2 prior lines of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), including a third generation TKI for participants with a T790M mutation; and 1 platinum-based therapy after progression on or after EGFR TKI.",
      "* Measurable disease per RECIST 1.1 as assessed by the local site investigator.",
      "* Archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided",
      "* Participants who have AEs due to previous anticancer therapies must have recovered to Grade ≤1 or baseline.",
      "* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to randomization.",
      "* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.",
      "* Have an ECOG performance status of 0 or 1 within 3 days before randomization.",
      "",
      "Exclusion Criteria:",
      "",
      "* Has predominantly squamous cell histology NSCLC.",
      "* Has mixed tumor(s) with small cell elements.",
      "* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease.",
      "* Has Grade ≥2 peripheral neuropathy.",
      "* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing.",
      "* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease.",
      "* Has an EGFR T790M mutation and has not received a third generation EGFR TKI (eg, osimertinib).",
      "* Received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before randomization.",
      "* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.",
      "* Completed palliative radiotherapy within 7 days of the first dose. Participants must have recovered from all radiation-related toxicities and not require corticosteroids.",
      "* Received radiation therapy to the lung that is \\>30 Gy within 6 months of the first dose of study intervention.",
      "* Received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC).",
      "* Received prior treatment with a topoisomerase I-containing ADC.",
      "* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.",
      "* Known additional malignancy that is progressing or has required active treatment within the past 3 years.",
      "* Active infection requiring systemic therapy.",
      "* History of noninfectious pneumonitis/ILD that required steroids or has current pneumonitis/ILD.",
      "* Has known active central nervous system metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are clinically stable for at least 2 weeks, and are off steroids 3 days prior to dosing with study medication.",
      "* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.",
      "* Concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV DNA) and Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA) infection."
    ],
    "exclusion_criteria": [
      "The main inclusion and exclusion criteria include but are not limited to the following:",
      "",
      "Inclusion Criteria:",
      "",
      "* Histologically- or cytologically-documented advanced (Stage III not eligible for resection or curative radiation) or metastatic non-squamous NSCLC with specific mutations.",
      "* Documentation of locally assessed radiological disease progression while on or after last treatment based on Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1.",
      "* Participants with genome mutations must have received 1 or 2 prior lines of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), including a third generation TKI for participants with a T790M mutation; and 1 platinum-based therapy after progression on or after EGFR TKI.",
      "* Measurable disease per RECIST 1.1 as assessed by the local site investigator.",
      "* Archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided",
      "* Participants who have AEs due to previous anticancer therapies must have recovered to Grade ≤1 or baseline.",
      "* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to randomization.",
      "* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.",
      "* Have an ECOG performance status of 0 or 1 within 3 days before randomization.",
      "",
      "Exclusion Criteria:",
      "",
      "* Has predominantly squamous cell histology NSCLC.",
      "* Has mixed tumor(s) with small cell elements.",
      "* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease.",
      "* Has Grade ≥2 peripheral neuropathy.",
      "* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing.",
      "* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease.",
      "* Has an EGFR T790M mutation and has not received a third generation EGFR TKI (eg, osimertinib).",
      "* Received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before randomization.",
      "* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.",
      "* Completed palliative radiotherapy within 7 days of the first dose. Participants must have recovered from all radiation-related toxicities and not require corticosteroids.",
      "* Received radiation therapy to the lung that is \\>30 Gy within 6 months of the first dose of study intervention.",
      "* Received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC).",
      "* Received prior treatment with a topoisomerase I-containing ADC.",
      "* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.",
      "* Known additional malignancy that is progressing or has required active treatment within the past 3 years.",
      "* Active infection requiring systemic therapy.",
      "* History of noninfectious pneumonitis/ILD that required steroids or has current pneumonitis/ILD.",
      "* Has known active central nervous system metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are clinically stable for at least 2 weeks, and are off steroids 3 days prior to dosing with study medication.",
      "* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.",
      "* Concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV DNA) and Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA) infection."
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "Not specified",
    "status": "RECRUITING",
    "start_date": "2023-11-12",
    "completion_date": "2030-03-11",
    "sponsor": "Unknown",
    "last_updated": "2025-05-16"
  },
  {
    "id": "NCT05609968",
    "title": "An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)",
    "phase": "PHASE3",
    "description": "No description provided.",
    "inclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "The main inclusion criteria include but are not limited to the following:",
      "",
      "* Has a histologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer (NSCLC)",
      "* Has confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase 1 (ALK-1), or ROS proto-oncogene 1 (ROS-1)-directed therapy is not indicated as primary therapy",
      "* Has provided tumor tissue that demonstrates PD-L1 tumor proportion score (TPS) ≥50% of tumor cells as assessed by immunohistochemistry (IHC) at a central laboratory",
      "* Has a life expectancy of at least 3 months",
      "",
      "Exclusion Criteria:",
      "",
      "The main exclusion criteria include but are not limited to the following:",
      "",
      "* Has history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years",
      "* Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC",
      "* Has previously received treatment with Topoisomerase 1 inhibitors or Trop-2 targeted therapy",
      "* Has received prior therapy with an anti-programmed cell death 1 protein (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti anti- programmed cell death ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor",
      "* Has received prior radiotherapy within 2 weeks of start of study intervention or has radiation-related toxicities requiring corticosteroids",
      "* Has received radiation therapy to the lung that is \\>30 Gray (Gy) within 6 months of the first dose of study intervention",
      "* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention",
      "* Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration",
      "* Has cardiac disease",
      "",
      "  * Myocardial infarction or unstable angina pectoris within 6 months of enrollment",
      "  * History of serious ventricular arrhythmia, high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications; history of QT interval prolongation",
      "  * New York Heart Association (NYHA) Class III or greater congestive heart failure or left ventricular ejection fraction of \\<40%",
      "* Has active chronic inflammatory bowel disease",
      "* Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication",
      "* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis",
      "* Has severe hypersensitivity (≥Grade 3) to pembrolizumab or sacituzumab govitecan and/or any of their excipients",
      "* Has active autoimmune disease that has required systemic treatment in past 2 years except replacement therapy",
      "* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease",
      "* Has active infection requiring systemic therapy",
      "* Has history of human immunodeficiency virus (HIV) infection",
      "* History of hepatitis B or known active hepatitis C virus infection",
      "* Has history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator",
      "* Have not adequately recovered from major surgery or have ongoing surgical complications"
    ],
    "exclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "The main inclusion criteria include but are not limited to the following:",
      "",
      "* Has a histologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer (NSCLC)",
      "* Has confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase 1 (ALK-1), or ROS proto-oncogene 1 (ROS-1)-directed therapy is not indicated as primary therapy",
      "* Has provided tumor tissue that demonstrates PD-L1 tumor proportion score (TPS) ≥50% of tumor cells as assessed by immunohistochemistry (IHC) at a central laboratory",
      "* Has a life expectancy of at least 3 months",
      "",
      "Exclusion Criteria:",
      "",
      "The main exclusion criteria include but are not limited to the following:",
      "",
      "* Has history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years",
      "* Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC",
      "* Has previously received treatment with Topoisomerase 1 inhibitors or Trop-2 targeted therapy",
      "* Has received prior therapy with an anti-programmed cell death 1 protein (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti anti- programmed cell death ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor",
      "* Has received prior radiotherapy within 2 weeks of start of study intervention or has radiation-related toxicities requiring corticosteroids",
      "* Has received radiation therapy to the lung that is \\>30 Gray (Gy) within 6 months of the first dose of study intervention",
      "* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention",
      "* Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration",
      "* Has cardiac disease",
      "",
      "  * Myocardial infarction or unstable angina pectoris within 6 months of enrollment",
      "  * History of serious ventricular arrhythmia, high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications; history of QT interval prolongation",
      "  * New York Heart Association (NYHA) Class III or greater congestive heart failure or left ventricular ejection fraction of \\<40%",
      "* Has active chronic inflammatory bowel disease",
      "* Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication",
      "* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis",
      "* Has severe hypersensitivity (≥Grade 3) to pembrolizumab or sacituzumab govitecan and/or any of their excipients",
      "* Has active autoimmune disease that has required systemic treatment in past 2 years except replacement therapy",
      "* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease",
      "* Has active infection requiring systemic therapy",
      "* Has history of human immunodeficiency virus (HIV) infection",
      "* History of hepatitis B or known active hepatitis C virus infection",
      "* Has history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator",
      "* Have not adequately recovered from major surgery or have ongoing surgical complications"
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "Not specified",
    "status": "RECRUITING",
    "start_date": "2023-02-06",
    "completion_date": "2028-08-23",
    "sponsor": "Unknown",
    "last_updated": "2024-11-18"
  },
  {
    "id": "NCT05703997",
    "title": "FASTing-like Approach to Improve the Efficacy of Maintenance IMMunotherapy in Extensive-stage Small Cell Lung Cancer Patients Not Progressing on Chemoimmunotherapy Induction: the FASTIMMUNE Trial",
    "phase": "PHASE2",
    "description": "No description provided.",
    "inclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Participants who are able to comply with the requirements and restrictions listed in the Informed Consent Form and the study protocol (there is no separate Informed Consent Form for entering the maintenance phase)",
      "* Signature of the informed consent form for those patients who have not previously participated to the induction phase of the study",
      "* Age greater than or equal to 18 years and less than or equal to 75 years",
      "* Willingness and ability to comply with the prescribed cyclic, 5-day calorie restriction regimen, the scheduled visits, treatment plans, laboratory tests and other procedures",
      "* Histologically or cytologically confirmed diagnosis of small-cell lung cancer (SCLC).",
      "* Radiological evidence of extensive-stage (ES) disease.",
      "* Patient has available archival tumor tissue. Patients for whom only cytological material is available may be enrolled only if cytoincluded material is available.",
      "* Patients must have received a first-line, chemoimmunotherapy induction with 4 triweekly cycles of atezolizumab plus carboplatin and etoposide, with the last cycle of induction chemoimmunotherapy administered not more than six weeks before the initiation of experimental maintenance treatment. Delays between cycles of chemoimmunotherapy due to the occurrence of AEs or other medical reasons are considered acceptable, provided that a total number of 4 cycles of chemoimmunotherapy with atezolizumab plus carboplatin and etoposide have been administered, and that there is no radiological evidence of disease progression.",
      "* Radiological evidence of nonprogressive disease after chemoimmunotherapy induction with 4 triweekly cycles of atezolizumab plus carboplatin and etoposide.",
      "* Patients with a history of treated CNS metastases are eligible, if there is no evidence of interim progression between the completion of CNS-directed therapy and the experimental maintenance treatment initiation, and if CNS metastases are asymptomatic.",
      "* An Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.",
      "* Presence of an adequate bone marrow and organ function",
      "* Female patients of childbearing potential must agree to abstinence from heterosexual intercourse or to use two highly effective methods of contraception throughout the study and for at least six months after the end of the maintenance treatment.",
      "* Female patients are not of childbearing potential if they meet at least one of the following criteria:",
      "",
      "  1. Have undergone a documented hysterectomy and/or bilateral oophorectomy",
      "  2. Have medically confirmed ovarian failure",
      "  3. Achieved post-menopausal status",
      "* Male patients must agree to abstinence from heterosexual intercourse or to use two highly effective methods of contraception during sexual contact with a female with childbearing potential throughout the study and for at least six months after the end of the maintenance treatment.",
      "",
      "Exclusion Criteria:",
      "",
      "* Prior systemic treatment for ES SCLC, with the exception for first-line chemoimmunotherapy induction with 4 triweekly cycles of atezolizumab plus carboplatin and etoposide. Patients who received prior concurrent chemoradiotherapy for limited-stage (LS) disease may be enrolled if concurrent chemoradiotherapy was concluded at least three months before enrollment.",
      "* Patient has not available archival tumor tissue or has only cytological material without cytoincluded material available.",
      "* The patient has not recovered from immune-related AEs of grade 2 or higher from the induction phase with atezolizumab plus carboplatin and etoposide. Patients with adequately-treated, controlled, immune-related skin rash of grade 2 or adequately-treated, controlled, endocrinopathies of grade 2 on replacement therapy can be enrolled.",
      "* Body mass index (BMI) \\< 19 kg/m2.",
      "* Unintentional weight loss ≥ 5% in the previous 3 months, unless the patient has a BMI \\> 22 kg/m2 and weight loss has been lower than 10% at the time of enrollment in the study; or unintentional weight loss ≥ 10% in the previous 3 months, unless the patient has a BMI \\> 25 kg/m2 and weight loss has been lower than 15% at the time of the enrollment in the study. In all cases, weight must have been stable for at least one month before study enrollment.",
      "* Baseline plasma glucose concentration ≤ 60 mg/dL (after at least 8 hours fasting)",
      "* Diagnosis of any other malignancy within 2 years prior to enrollment, with the exception of adequately treated in-situ bladder cancer, in-situ carcinoma of the cervix, uteri, non-melanomatous skin cancer, ductal in-situ breast cancer, thyroid cancer or early-stage prostate cancer (all treatment of which should have been completed at least 6 months prior to enrollment)",
      "* Asymptomatic and untreated, symptomatic or unstable CNS metastases as determined by CT-scan or MRI evaluation during screening and/or prior radiographic assessments.",
      "* Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated but not clinically stable for ≥ 4 weeks prior to the experimental maintenance treatment initiation.",
      "* Leptomeningeal disease.",
      "* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently).",
      "* History of alcohol abuse.",
      "* Active pregnancy or breastfeeding.",
      "* Known active B or C hepatitis or human immunodeficiency virus (HIV) infection, or occasional finding of active hepatitis B/C infection during screening tests before experimental treatment initiation.",
      "* Serious infections in the previous 4 weeks before the experimental maintenance treatment initiation.",
      "* Active autoimmune diseases requiring systemic treatments (e.g., systemic steroids or immunosuppressants).",
      "* Other medical conditions requiring active chronic therapy with systemic steroids at a dose ≥ 10 mg per day of prednisone or equivalent or other immunosuppressive medications within 14 days before the experimental maintenance treatment initiation.",
      "* Adrenal replacement steroid doses ≥ 10 mg per day of prednisone or equivalent are permitted in the absence of active autoimmune disease",
      "* Diagnosis of type 1 or 2 diabetes mellitus requiring pharmacologic therapy (including, but not limited to, insulin and secretagogues). A diagnosis of type 2 diabetes mellitus not requiring insulin and secretagogues on the judgment of a diabetologist and treated with metformin or alpha-glucosidase inhibitors (e.g., acarbose) is compatible with patient enrollment in the trial.",
      "* Active gastric or intestinal ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small intestine resection.",
      "* Anamnesis of clinically significant heart disease including:",
      "",
      "  1. angina pectoris, coronary bypass, symptomatic pericarditis, myocardial infarction in the previous 12 months from the beginning of experimental maintenance treatment.",
      "  2. congestive heart failure NYHA class III-IV.",
      "  3. cardiac arrhythmias, such as ventricular tachycardia, chronic atrial fibrillation, complete bundle branch block, high grade atrio-ventricular block like bi-fascicular block, type II Mobitz and third grade atrio-ventricular block, nodal arrhythmias, supra-ventricular arrhythmias.",
      "* Previous episodes of symptomatic hypotension leading to loss of consciousness.",
      "* Medical or psychiatric comorbidities rendering the patient not candidate to the clinical trial, according to the investigator's judgement.",
      "* Other cardiac, liver, lung or renal comorbidities, not specified in the previous inclusion or exclusion criteria, but potentially exposing the patient to a high risk of lactic acidosis."
    ],
    "exclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Participants who are able to comply with the requirements and restrictions listed in the Informed Consent Form and the study protocol (there is no separate Informed Consent Form for entering the maintenance phase)",
      "* Signature of the informed consent form for those patients who have not previously participated to the induction phase of the study",
      "* Age greater than or equal to 18 years and less than or equal to 75 years",
      "* Willingness and ability to comply with the prescribed cyclic, 5-day calorie restriction regimen, the scheduled visits, treatment plans, laboratory tests and other procedures",
      "* Histologically or cytologically confirmed diagnosis of small-cell lung cancer (SCLC).",
      "* Radiological evidence of extensive-stage (ES) disease.",
      "* Patient has available archival tumor tissue. Patients for whom only cytological material is available may be enrolled only if cytoincluded material is available.",
      "* Patients must have received a first-line, chemoimmunotherapy induction with 4 triweekly cycles of atezolizumab plus carboplatin and etoposide, with the last cycle of induction chemoimmunotherapy administered not more than six weeks before the initiation of experimental maintenance treatment. Delays between cycles of chemoimmunotherapy due to the occurrence of AEs or other medical reasons are considered acceptable, provided that a total number of 4 cycles of chemoimmunotherapy with atezolizumab plus carboplatin and etoposide have been administered, and that there is no radiological evidence of disease progression.",
      "* Radiological evidence of nonprogressive disease after chemoimmunotherapy induction with 4 triweekly cycles of atezolizumab plus carboplatin and etoposide.",
      "* Patients with a history of treated CNS metastases are eligible, if there is no evidence of interim progression between the completion of CNS-directed therapy and the experimental maintenance treatment initiation, and if CNS metastases are asymptomatic.",
      "* An Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.",
      "* Presence of an adequate bone marrow and organ function",
      "* Female patients of childbearing potential must agree to abstinence from heterosexual intercourse or to use two highly effective methods of contraception throughout the study and for at least six months after the end of the maintenance treatment.",
      "* Female patients are not of childbearing potential if they meet at least one of the following criteria:",
      "",
      "  1. Have undergone a documented hysterectomy and/or bilateral oophorectomy",
      "  2. Have medically confirmed ovarian failure",
      "  3. Achieved post-menopausal status",
      "* Male patients must agree to abstinence from heterosexual intercourse or to use two highly effective methods of contraception during sexual contact with a female with childbearing potential throughout the study and for at least six months after the end of the maintenance treatment.",
      "",
      "Exclusion Criteria:",
      "",
      "* Prior systemic treatment for ES SCLC, with the exception for first-line chemoimmunotherapy induction with 4 triweekly cycles of atezolizumab plus carboplatin and etoposide. Patients who received prior concurrent chemoradiotherapy for limited-stage (LS) disease may be enrolled if concurrent chemoradiotherapy was concluded at least three months before enrollment.",
      "* Patient has not available archival tumor tissue or has only cytological material without cytoincluded material available.",
      "* The patient has not recovered from immune-related AEs of grade 2 or higher from the induction phase with atezolizumab plus carboplatin and etoposide. Patients with adequately-treated, controlled, immune-related skin rash of grade 2 or adequately-treated, controlled, endocrinopathies of grade 2 on replacement therapy can be enrolled.",
      "* Body mass index (BMI) \\< 19 kg/m2.",
      "* Unintentional weight loss ≥ 5% in the previous 3 months, unless the patient has a BMI \\> 22 kg/m2 and weight loss has been lower than 10% at the time of enrollment in the study; or unintentional weight loss ≥ 10% in the previous 3 months, unless the patient has a BMI \\> 25 kg/m2 and weight loss has been lower than 15% at the time of the enrollment in the study. In all cases, weight must have been stable for at least one month before study enrollment.",
      "* Baseline plasma glucose concentration ≤ 60 mg/dL (after at least 8 hours fasting)",
      "* Diagnosis of any other malignancy within 2 years prior to enrollment, with the exception of adequately treated in-situ bladder cancer, in-situ carcinoma of the cervix, uteri, non-melanomatous skin cancer, ductal in-situ breast cancer, thyroid cancer or early-stage prostate cancer (all treatment of which should have been completed at least 6 months prior to enrollment)",
      "* Asymptomatic and untreated, symptomatic or unstable CNS metastases as determined by CT-scan or MRI evaluation during screening and/or prior radiographic assessments.",
      "* Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated but not clinically stable for ≥ 4 weeks prior to the experimental maintenance treatment initiation.",
      "* Leptomeningeal disease.",
      "* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently).",
      "* History of alcohol abuse.",
      "* Active pregnancy or breastfeeding.",
      "* Known active B or C hepatitis or human immunodeficiency virus (HIV) infection, or occasional finding of active hepatitis B/C infection during screening tests before experimental treatment initiation.",
      "* Serious infections in the previous 4 weeks before the experimental maintenance treatment initiation.",
      "* Active autoimmune diseases requiring systemic treatments (e.g., systemic steroids or immunosuppressants).",
      "* Other medical conditions requiring active chronic therapy with systemic steroids at a dose ≥ 10 mg per day of prednisone or equivalent or other immunosuppressive medications within 14 days before the experimental maintenance treatment initiation.",
      "* Adrenal replacement steroid doses ≥ 10 mg per day of prednisone or equivalent are permitted in the absence of active autoimmune disease",
      "* Diagnosis of type 1 or 2 diabetes mellitus requiring pharmacologic therapy (including, but not limited to, insulin and secretagogues). A diagnosis of type 2 diabetes mellitus not requiring insulin and secretagogues on the judgment of a diabetologist and treated with metformin or alpha-glucosidase inhibitors (e.g., acarbose) is compatible with patient enrollment in the trial.",
      "* Active gastric or intestinal ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small intestine resection.",
      "* Anamnesis of clinically significant heart disease including:",
      "",
      "  1. angina pectoris, coronary bypass, symptomatic pericarditis, myocardial infarction in the previous 12 months from the beginning of experimental maintenance treatment.",
      "  2. congestive heart failure NYHA class III-IV.",
      "  3. cardiac arrhythmias, such as ventricular tachycardia, chronic atrial fibrillation, complete bundle branch block, high grade atrio-ventricular block like bi-fascicular block, type II Mobitz and third grade atrio-ventricular block, nodal arrhythmias, supra-ventricular arrhythmias.",
      "* Previous episodes of symptomatic hypotension leading to loss of consciousness.",
      "* Medical or psychiatric comorbidities rendering the patient not candidate to the clinical trial, according to the investigator's judgement.",
      "* Other cardiac, liver, lung or renal comorbidities, not specified in the previous inclusion or exclusion criteria, but potentially exposing the patient to a high risk of lactic acidosis."
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "75 Years",
    "status": "NOT_YET_RECRUITING",
    "start_date": "2023-01",
    "completion_date": "2029-01",
    "sponsor": "Unknown",
    "last_updated": "2023-01-30"
  },
  {
    "id": "NCT06422143",
    "title": "Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer",
    "phase": "PHASE3",
    "description": "No description provided.",
    "inclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Histologically or cytologically confirmed diagnosis of squamous non-small cell lung cancer (NSCLC) \\[Stage IV: M1a, M1b, M1c, American Joint Committee on Cancer Staging Manual, version 8\\]",
      "* Measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 as assessed by the local site investigator/radiology",
      "* Has life expectancy ≥3 months",
      "* Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 assessed within 7 days prior to allocation",
      "* Archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided",
      "* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)",
      "* Participants who are hepatitis B surface antigen (HBsAg)-positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before allocation",
      "* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening",
      "* Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to ≤ Grade 1 or baseline (participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible)",
      "* Has adequate organ function",
      "* For Maintenance only (prior to randomization): is without disease progression of their NSCLC, as determined by BICR using RECIST 1.1 after completion of study-specified Induction with an evaluable scan at Week 12",
      "* For Maintenance only (prior to randomization): has ECOG PS of 0 or 1 as assessed at the Prerandomization Visit",
      "* For Maintenance only (prior to randomization): all AEs (with the exception of alopecia, Grade 2 fatigue, and Grade ≤2 endocrine-related AEs requiring treatment or hormone replacement) have recovered",
      "",
      "Exclusion Criteria:",
      "",
      "* Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements",
      "* History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing",
      "* Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)",
      "* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to \\>480 ms, and other serious cardiovascular and cerebrovascular diseases within 6 months before study intervention",
      "* HIV-infected participants who have been newly diagnosed or with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease",
      "* Received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC",
      "* Received prior therapy with an anti-programmed cell death-1 (PD-1), anti-PD-Ligand 1 (PD-L1), or anti-PD-Lignad 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic Tlymphocyte-associated protein 4, OX-40, CD137) \\[Note: Prior treatment with chemotherapy and/or radiation as a part of neoadjuvant or adjuvant therapy or chemoradiation therapy for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC.\\]",
      "* Received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)-targeted antidrug conjugate (ADC)",
      "* Received radiation therapy to the lung that is \\>30 Gray within 6 months of start of study intervention",
      "* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids",
      "* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention",
      "* Participants who have not adequately recovered from major surgery or have ongoing surgical complications",
      "* Received prior treatment with a topoisomerase I inhibitor-containing ADC",
      "* Is currently receiving a strong inducer/inhibitor of CYP3A4 that cannot be discontinued for the duration of the study (the required washout period before starting sac-TMT is 2 weeks)",
      "* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.",
      "* Has known central nervous system (CNS) metastases/carcinomatous meningitis",
      "* Severe hypersensitivity (≥Grade 3) to study intervention and/or any of its excipients or to another biologic therapy",
      "* Active autoimmune disease that has required systemic treatment in the past 2 years (replacement therapy \\[eg, thyroxine, insulin, or physiologic corticosteroid\\] is allowed)",
      "* History of (noninfectious)pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease",
      "* Active infection requiring systemic therapy",
      "* History of allogeneic tissue/solid organ transplant"
    ],
    "exclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Histologically or cytologically confirmed diagnosis of squamous non-small cell lung cancer (NSCLC) \\[Stage IV: M1a, M1b, M1c, American Joint Committee on Cancer Staging Manual, version 8\\]",
      "* Measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 as assessed by the local site investigator/radiology",
      "* Has life expectancy ≥3 months",
      "* Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 assessed within 7 days prior to allocation",
      "* Archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided",
      "* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)",
      "* Participants who are hepatitis B surface antigen (HBsAg)-positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before allocation",
      "* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening",
      "* Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to ≤ Grade 1 or baseline (participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible)",
      "* Has adequate organ function",
      "* For Maintenance only (prior to randomization): is without disease progression of their NSCLC, as determined by BICR using RECIST 1.1 after completion of study-specified Induction with an evaluable scan at Week 12",
      "* For Maintenance only (prior to randomization): has ECOG PS of 0 or 1 as assessed at the Prerandomization Visit",
      "* For Maintenance only (prior to randomization): all AEs (with the exception of alopecia, Grade 2 fatigue, and Grade ≤2 endocrine-related AEs requiring treatment or hormone replacement) have recovered",
      "",
      "Exclusion Criteria:",
      "",
      "* Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements",
      "* History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing",
      "* Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)",
      "* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to \\>480 ms, and other serious cardiovascular and cerebrovascular diseases within 6 months before study intervention",
      "* HIV-infected participants who have been newly diagnosed or with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease",
      "* Received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC",
      "* Received prior therapy with an anti-programmed cell death-1 (PD-1), anti-PD-Ligand 1 (PD-L1), or anti-PD-Lignad 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic Tlymphocyte-associated protein 4, OX-40, CD137) \\[Note: Prior treatment with chemotherapy and/or radiation as a part of neoadjuvant or adjuvant therapy or chemoradiation therapy for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC.\\]",
      "* Received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)-targeted antidrug conjugate (ADC)",
      "* Received radiation therapy to the lung that is \\>30 Gray within 6 months of start of study intervention",
      "* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids",
      "* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention",
      "* Participants who have not adequately recovered from major surgery or have ongoing surgical complications",
      "* Received prior treatment with a topoisomerase I inhibitor-containing ADC",
      "* Is currently receiving a strong inducer/inhibitor of CYP3A4 that cannot be discontinued for the duration of the study (the required washout period before starting sac-TMT is 2 weeks)",
      "* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.",
      "* Has known central nervous system (CNS) metastases/carcinomatous meningitis",
      "* Severe hypersensitivity (≥Grade 3) to study intervention and/or any of its excipients or to another biologic therapy",
      "* Active autoimmune disease that has required systemic treatment in the past 2 years (replacement therapy \\[eg, thyroxine, insulin, or physiologic corticosteroid\\] is allowed)",
      "* History of (noninfectious)pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease",
      "* Active infection requiring systemic therapy",
      "* History of allogeneic tissue/solid organ transplant"
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "Not specified",
    "status": "RECRUITING",
    "start_date": "2024-06-10",
    "completion_date": "2031-02-12",
    "sponsor": "Unknown",
    "last_updated": "2025-05-16"
  },
  {
    "id": "NCT05676931",
    "title": "A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer",
    "phase": "PHASE2",
    "description": "No description provided.",
    "inclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Histologically or cytologically documented Stage IV metastatic, NSCLC",
      "* Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1",
      "* At least one measurable target lesion per RECIST v1.1.",
      "* Adequate organ function",
      "* Participants must be willing to provide adequate tumor tissue",
      "",
      "Exclusion Criteria:",
      "",
      "* Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of Investigational Product(s) (IPs) hazardous",
      "* Use of any live vaccines against infectious diseases within 28 days of first dose of IP(s).",
      "* Use of supra-physiologic doses of corticosteroids (\\> 10 mg/day of oral prednisone or equivalent) or immunosuppressive medications ≤ 14 days before the initiation of study treatment (absorbable topical corticosteroids are not excluded).",
      "* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.",
      "* Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy",
      "",
      "NOTE: Other protocol defined Inclusion/Exclusion criteria may apply."
    ],
    "exclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Histologically or cytologically documented Stage IV metastatic, NSCLC",
      "* Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1",
      "* At least one measurable target lesion per RECIST v1.1.",
      "* Adequate organ function",
      "* Participants must be willing to provide adequate tumor tissue",
      "",
      "Exclusion Criteria:",
      "",
      "* Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of Investigational Product(s) (IPs) hazardous",
      "* Use of any live vaccines against infectious diseases within 28 days of first dose of IP(s).",
      "* Use of supra-physiologic doses of corticosteroids (\\> 10 mg/day of oral prednisone or equivalent) or immunosuppressive medications ≤ 14 days before the initiation of study treatment (absorbable topical corticosteroids are not excluded).",
      "* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.",
      "* Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy",
      "",
      "NOTE: Other protocol defined Inclusion/Exclusion criteria may apply."
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "Not specified",
    "status": "RECRUITING",
    "start_date": "2023-02-21",
    "completion_date": "2027-12",
    "sponsor": "Unknown",
    "last_updated": "2025-03-21"
  },
  {
    "id": "NCT06452277",
    "title": "A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations",
    "phase": "PHASE3",
    "description": "No description provided.",
    "inclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Participant must be ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signing the informed consent.",
      "* Documented histologically or cytologically confirmed locally advanced non-squamous NSCLC, not suitable for definitive therapy or metastatic non-squamous NSCLC at screening (small cell or mixed histologies are excluded) (Stage III-IV NSCLC).",
      "* Documented activating HER2 mutation in the tyrosine kinase domain (TKD) assessed by tissue molecular test in a CLIA-certified (US sites) or an equally accredited (outside of the US) local laboratory. However, participants may be included at the discretion of the investigator if the laboratory performing the assay is not CLIA or similar certified but the laboratory is locally accredited.",
      "* No prior systemic therapy for locally advanced or metastatic disease. No prior treatment with a HER2 ex20ins-targeted therapy (e.g. poziotinib, trastuzumab deruxtecan). Participants who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the start of screening.",
      "* Eligible to receive treatment with the selected platinum-based doublet-chemotherapy (i.e. cisplatin/pemetrexed or carboplatin/pemetrexed) and pembrolizumab in accordance with the SmPC/Product Information.",
      "",
      "Exclusion Criteria:",
      "",
      "* Known history of prior malignancy except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for five years since initiation of that therapy. Exception: the following cancer types are acceptable within five years if curatively treated or under surveillance:",
      "",
      "  * a. in situ cancers of cervix, breast, or skin,",
      "  * b. superficial bladder cancer (Ta, Tis and T1),",
      "  * c. limited-stage prostate cancer,",
      "  * d. basal or squamous cancers of the skin.",
      "* Tumors with targetable alterations with approved available therapy, with the exception of HER2 mutation in the TKD.",
      "* Inability to discontinue treatment with chronic systemic corticosteroids. Participants who require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study. Replacement therapy (e.g., physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is acceptable, provided that the dose is stable for \\>4 weeks prior to planned start of study intervention.",
      "* Pre-existing peripheral neuropathy that is Grade ≥2 by CTCAE (v5.0).",
      "* History of severe hypersensitivity reaction to treatment with a monoclonal antibody.",
      "* Prior radiotherapy outside of the brain within 21 days of planned start of study intervention. Participants must have recovered from all radiation-related toxicities and not require corticosteroids."
    ],
    "exclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Participant must be ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signing the informed consent.",
      "* Documented histologically or cytologically confirmed locally advanced non-squamous NSCLC, not suitable for definitive therapy or metastatic non-squamous NSCLC at screening (small cell or mixed histologies are excluded) (Stage III-IV NSCLC).",
      "* Documented activating HER2 mutation in the tyrosine kinase domain (TKD) assessed by tissue molecular test in a CLIA-certified (US sites) or an equally accredited (outside of the US) local laboratory. However, participants may be included at the discretion of the investigator if the laboratory performing the assay is not CLIA or similar certified but the laboratory is locally accredited.",
      "* No prior systemic therapy for locally advanced or metastatic disease. No prior treatment with a HER2 ex20ins-targeted therapy (e.g. poziotinib, trastuzumab deruxtecan). Participants who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the start of screening.",
      "* Eligible to receive treatment with the selected platinum-based doublet-chemotherapy (i.e. cisplatin/pemetrexed or carboplatin/pemetrexed) and pembrolizumab in accordance with the SmPC/Product Information.",
      "",
      "Exclusion Criteria:",
      "",
      "* Known history of prior malignancy except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for five years since initiation of that therapy. Exception: the following cancer types are acceptable within five years if curatively treated or under surveillance:",
      "",
      "  * a. in situ cancers of cervix, breast, or skin,",
      "  * b. superficial bladder cancer (Ta, Tis and T1),",
      "  * c. limited-stage prostate cancer,",
      "  * d. basal or squamous cancers of the skin.",
      "* Tumors with targetable alterations with approved available therapy, with the exception of HER2 mutation in the TKD.",
      "* Inability to discontinue treatment with chronic systemic corticosteroids. Participants who require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study. Replacement therapy (e.g., physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is acceptable, provided that the dose is stable for \\>4 weeks prior to planned start of study intervention.",
      "* Pre-existing peripheral neuropathy that is Grade ≥2 by CTCAE (v5.0).",
      "* History of severe hypersensitivity reaction to treatment with a monoclonal antibody.",
      "* Prior radiotherapy outside of the brain within 21 days of planned start of study intervention. Participants must have recovered from all radiation-related toxicities and not require corticosteroids."
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "Not specified",
    "status": "RECRUITING",
    "start_date": "2024-08-28",
    "completion_date": "2029-04-26",
    "sponsor": "Unknown",
    "last_updated": "2025-04-08"
  },
  {
    "id": "NCT06170788",
    "title": "A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)",
    "phase": "PHASE3",
    "description": "No description provided.",
    "inclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Histologically or cytologically confirmed diagnosis of squamous or nonsquamous NSCLC",
      "",
      "  * Confirmation that epidermal growth factor receptor- (EGFR-), anaplastic lymphoma kinase- (ALK-), or proto-oncogene tyrosine-protein kinase ROS (ROS1-) directed therapy is not indicated as primary therapy",
      "  * Provided tumor tissue that demonstrates programmed cell death ligand 1 (PD-L1) expression in ≥50% of tumor cells as assessed by an immunohistochemistry (IHC) central laboratory",
      "  * An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization.",
      "  * A life expectancy of at least 3 months.",
      "  * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)",
      "",
      "Exclusion Criteria:",
      "",
      "* Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements.",
      "* Has Grade ≥2 peripheral neuropathy.",
      "* History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing.",
      "* Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea).",
      "* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease within the 6 months preceding study intervention.",
      "* Received prior systemic anticancer therapy for their metastatic NSCLC.",
      "* Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor Note: Prior treatment with an anti-PD-1, anti-PD- L1, or anti-PD-L2 agent in the neoadjuvant or adjuvant setting for nonmetastatic resectable NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC.",
      "* Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.",
      "* Received radiation therapy to the lung that is \\>30 Gy within 6 months of start of study intervention.",
      "* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.",
      "* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.",
      "* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy",
      "* Known additional malignancy that is progressing or has required active treatment within the past 3 years.",
      "* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.",
      "* Known intolerance to sacituzumab tirumotecan or pembrolizumab and/or any of their excipients; for pembrolizumab, severe hypersensitivity (≥Grade 3) is exclusionary.",
      "* Known hypersensitivity to sacituzumab tirumotecan or other biologic therapy.",
      "* Active autoimmune disease that has required systemic treatment in the past 2 years.",
      "* History of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids or has current pneumonitis/ILD.",
      "* Active infection requiring systemic therapy",
      "* Concurrent active Hepatitis B and Hepatitis C virus infection.",
      "* Human immunodeficiency virus (HIV)-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.",
      "* History of allogeneic tissue/solid organ transplant.",
      "* Requires treatment with a strong inhibitor or inducer of Cytochrome P450 3A4 (CYP3A4) at least 14 days before the first dose of study intervention and throughout the study."
    ],
    "exclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Histologically or cytologically confirmed diagnosis of squamous or nonsquamous NSCLC",
      "",
      "  * Confirmation that epidermal growth factor receptor- (EGFR-), anaplastic lymphoma kinase- (ALK-), or proto-oncogene tyrosine-protein kinase ROS (ROS1-) directed therapy is not indicated as primary therapy",
      "  * Provided tumor tissue that demonstrates programmed cell death ligand 1 (PD-L1) expression in ≥50% of tumor cells as assessed by an immunohistochemistry (IHC) central laboratory",
      "  * An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization.",
      "  * A life expectancy of at least 3 months.",
      "  * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)",
      "",
      "Exclusion Criteria:",
      "",
      "* Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements.",
      "* Has Grade ≥2 peripheral neuropathy.",
      "* History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing.",
      "* Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea).",
      "* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease within the 6 months preceding study intervention.",
      "* Received prior systemic anticancer therapy for their metastatic NSCLC.",
      "* Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor Note: Prior treatment with an anti-PD-1, anti-PD- L1, or anti-PD-L2 agent in the neoadjuvant or adjuvant setting for nonmetastatic resectable NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC.",
      "* Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.",
      "* Received radiation therapy to the lung that is \\>30 Gy within 6 months of start of study intervention.",
      "* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.",
      "* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.",
      "* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy",
      "* Known additional malignancy that is progressing or has required active treatment within the past 3 years.",
      "* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.",
      "* Known intolerance to sacituzumab tirumotecan or pembrolizumab and/or any of their excipients; for pembrolizumab, severe hypersensitivity (≥Grade 3) is exclusionary.",
      "* Known hypersensitivity to sacituzumab tirumotecan or other biologic therapy.",
      "* Active autoimmune disease that has required systemic treatment in the past 2 years.",
      "* History of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids or has current pneumonitis/ILD.",
      "* Active infection requiring systemic therapy",
      "* Concurrent active Hepatitis B and Hepatitis C virus infection.",
      "* Human immunodeficiency virus (HIV)-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.",
      "* History of allogeneic tissue/solid organ transplant.",
      "* Requires treatment with a strong inhibitor or inducer of Cytochrome P450 3A4 (CYP3A4) at least 14 days before the first dose of study intervention and throughout the study."
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "Not specified",
    "status": "RECRUITING",
    "start_date": "2023-12-15",
    "completion_date": "2030-05-27",
    "sponsor": "Unknown",
    "last_updated": "2025-05-11"
  },
  {
    "id": "NCT06077760",
    "title": "A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)",
    "phase": "PHASE3",
    "description": "No description provided.",
    "inclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "The main inclusion criteria include but are not limited to the following:",
      "",
      "* Has undergone margin negative, completely resected non-small cell lung cancer (NSCLC), and has pathological Stage II, IIIA, IIIB (N2) squamous or nonsquamous tumor, node, metastasis (TNM) staging per American Joint Committee on Cancer (AJCC) Eighth Edition guidelines.",
      "* Has no evidence of disease before randomization.",
      "* Has received at least one dose of adjuvant treatment with standard of care platinum doublet chemotherapy.",
      "* No more than 24 weeks have elapsed between surgical resection of curative intent and the first dose of pembrolizumab.",
      "* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization.",
      "* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening.",
      "* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).",
      "",
      "Exclusion Criteria:",
      "",
      "The main exclusion criteria include but are not limited to the following:",
      "",
      "* Diagnosis of small cell lung cancer (SCLC) or, for mixed tumors, presence of small cell elements, or has a neuroendocrine tumor with large cell components or a sarcomatoid carcinoma.",
      "* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.",
      "* Received prior neoadjuvant therapy for their current NSCLC diagnosis.",
      "* Received or is a candidate to receive radiotherapy for their current NSCLC diagnosis.",
      "* Received prior therapy with an anti-programmed cell death 1 protein (PD-1), anti-PD-ligand 1 (L1), or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor.",
      "* Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.",
      "* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.",
      "* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.",
      "* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication.",
      "* Known additional malignancy that is progressing or has required active treatment within the past 5 years.",
      "* Active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed.",
      "* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.",
      "* Active infection requiring systemic therapy."
    ],
    "exclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "The main inclusion criteria include but are not limited to the following:",
      "",
      "* Has undergone margin negative, completely resected non-small cell lung cancer (NSCLC), and has pathological Stage II, IIIA, IIIB (N2) squamous or nonsquamous tumor, node, metastasis (TNM) staging per American Joint Committee on Cancer (AJCC) Eighth Edition guidelines.",
      "* Has no evidence of disease before randomization.",
      "* Has received at least one dose of adjuvant treatment with standard of care platinum doublet chemotherapy.",
      "* No more than 24 weeks have elapsed between surgical resection of curative intent and the first dose of pembrolizumab.",
      "* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization.",
      "* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening.",
      "* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).",
      "",
      "Exclusion Criteria:",
      "",
      "The main exclusion criteria include but are not limited to the following:",
      "",
      "* Diagnosis of small cell lung cancer (SCLC) or, for mixed tumors, presence of small cell elements, or has a neuroendocrine tumor with large cell components or a sarcomatoid carcinoma.",
      "* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.",
      "* Received prior neoadjuvant therapy for their current NSCLC diagnosis.",
      "* Received or is a candidate to receive radiotherapy for their current NSCLC diagnosis.",
      "* Received prior therapy with an anti-programmed cell death 1 protein (PD-1), anti-PD-ligand 1 (L1), or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor.",
      "* Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.",
      "* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.",
      "* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.",
      "* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication.",
      "* Known additional malignancy that is progressing or has required active treatment within the past 5 years.",
      "* Active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed.",
      "* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.",
      "* Active infection requiring systemic therapy."
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "Not specified",
    "status": "RECRUITING",
    "start_date": "2023-12-06",
    "completion_date": "2035-12-21",
    "sponsor": "Unknown",
    "last_updated": "2025-05-13"
  },
  {
    "id": "NCT06119581",
    "title": "SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression",
    "phase": "PHASE3",
    "description": "No description provided.",
    "inclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Histologically or cytologically confirmed NSCLC with Stage IIIB-IIIC or Stage IV disease, not suitable for curative intent radical surgery or radiation therapy.",
      "* Part B and Safety Lead-In Part B: the histology of the tumor must be predominantly non-squamous (in line with pemetrexed label).",
      "* Must have disease with evidence of KRAS G12C mutation.",
      "* Must have known programmed death-ligand 1 (PD-L1) expression",
      "",
      "  * Part A: Greater than or equal to (≥)50 percent (%).",
      "  * Part B: 0% to 100%.",
      "* Must have measurable disease per RECIST v1.1.",
      "* Must have an ECOG performance status of 0 or 1.",
      "* Estimated life expectancy ≥12 weeks.",
      "* Ability to swallow capsules.",
      "* Must have adequate laboratory parameters.",
      "* Contraceptive use should be consistent with local regulations for those participating in clinical studies.",
      "* Women of childbearing potential must",
      "",
      "  * Have a negative pregnancy test.",
      "  * Not be breastfeeding during treatment",
      "",
      "Exclusion Criteria:",
      "",
      "* Have a documented additional validated targetable oncogenic driver mutation or alteration in genes such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF (V600E), human epidermal growth factor receptor 2 (HER2), MET (exon 14), ROS1, rearranged during transfection (RET), or neurotrophic tyrosine receptor kinase (NTRK)1/2/3.",
      "* Have had any of the following prior to randomization:",
      "",
      "  -- Prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for advanced or metastatic NSCLC.",
      "",
      "  --- 1 cycle of standard-of-care treatment prior to study enrollment will be allowed for cases where immediate treatment is clinically indicated:",
      "* Have known active central nervous system metastases and/or carcinomatous meningitis.",
      "",
      "Exclusion Criteria for Participants receiving Pemetrexed and Platinum (Part B and Safety Lead-In Part B)",
      "",
      "* Have predominantly squamous cell histology for NSCLC",
      "* Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)",
      "* Is unable or unwilling to take folic acid or vitamin B12 supplementation."
    ],
    "exclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Histologically or cytologically confirmed NSCLC with Stage IIIB-IIIC or Stage IV disease, not suitable for curative intent radical surgery or radiation therapy.",
      "* Part B and Safety Lead-In Part B: the histology of the tumor must be predominantly non-squamous (in line with pemetrexed label).",
      "* Must have disease with evidence of KRAS G12C mutation.",
      "* Must have known programmed death-ligand 1 (PD-L1) expression",
      "",
      "  * Part A: Greater than or equal to (≥)50 percent (%).",
      "  * Part B: 0% to 100%.",
      "* Must have measurable disease per RECIST v1.1.",
      "* Must have an ECOG performance status of 0 or 1.",
      "* Estimated life expectancy ≥12 weeks.",
      "* Ability to swallow capsules.",
      "* Must have adequate laboratory parameters.",
      "* Contraceptive use should be consistent with local regulations for those participating in clinical studies.",
      "* Women of childbearing potential must",
      "",
      "  * Have a negative pregnancy test.",
      "  * Not be breastfeeding during treatment",
      "",
      "Exclusion Criteria:",
      "",
      "* Have a documented additional validated targetable oncogenic driver mutation or alteration in genes such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF (V600E), human epidermal growth factor receptor 2 (HER2), MET (exon 14), ROS1, rearranged during transfection (RET), or neurotrophic tyrosine receptor kinase (NTRK)1/2/3.",
      "* Have had any of the following prior to randomization:",
      "",
      "  -- Prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for advanced or metastatic NSCLC.",
      "",
      "  --- 1 cycle of standard-of-care treatment prior to study enrollment will be allowed for cases where immediate treatment is clinically indicated:",
      "* Have known active central nervous system metastases and/or carcinomatous meningitis.",
      "",
      "Exclusion Criteria for Participants receiving Pemetrexed and Platinum (Part B and Safety Lead-In Part B)",
      "",
      "* Have predominantly squamous cell histology for NSCLC",
      "* Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)",
      "* Is unable or unwilling to take folic acid or vitamin B12 supplementation."
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "Not specified",
    "status": "RECRUITING",
    "start_date": "2023-12-21",
    "completion_date": "2029-10",
    "sponsor": "Unknown",
    "last_updated": "2025-05-07"
  },
  {
    "id": "NCT06117774",
    "title": "A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy",
    "phase": "PHASE3",
    "description": "No description provided.",
    "inclusion_criteria": [
      "Inclusion Criteria: -Participants are eligible to be included in the study only if all of the following criteria apply:",
      "",
      "* Participant has provided informed consent prior to initiation of any study specific activities/procedures.",
      "* Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years).",
      "* Histologically or cytologically confirmed small-cell lung cancer (SCLC).",
      "* Diagnosed and treated for LS-SCLC with concurrent chemotherapy and radiotherapy.",
      "* Has completed chemoradiotherapy without progression per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1.) (ie, achieved complete response \\[CR\\], partial response \\[PR\\], or stable disease \\[SD\\]).",
      "* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.",
      "* Minimum life expectancy of 12 weeks.",
      "* Adequate organ function.",
      "* Toxicities attributed to concurrent chemoradiotherapy resolved to grade ≤ 1, unless otherwise specified. Excluding alopecia or fatigue.",
      "",
      "Exclusion Criteria: -Participants are excluded from the study if any of the following criteria apply:",
      "",
      "Disease Related",
      "",
      "* Extensive-stage SCLC (ES-SCLC).",
      "* Any previous diagnosis of transformed non-small-cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) activating mutation positive NSCLC that has transformed to SCLC, or mixed SCLC NSCLC histology.",
      "* Evidence of interstitial lung disease or active, non-infectious pneumonitis. Other Medical Conditions",
      "* History of other malignancy within the past 2 years, with certain exceptions.",
      "* History of solid organ transplantation.",
      "* Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association \\> class II) within 6 months prior to first dose of study treatment.",
      "* History of arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months prior to first dose of study treatment.",
      "* Exclusion of human immunodeficiency virus (HIV) and/or hepatitis infection based on criteria per protocol.",
      "* Participant with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of study treatment.",
      "",
      "Prior/Concomitant Therapy",
      "",
      "* Received sequential chemotherapy and thoracic radiotherapy (no overlap of thoracic radiotherapy with chemotherapy) during chemoradiation.",
      "* Prior therapy with any selective inhibitor of the delta-like ligand 3 (DLL3) pathway.",
      "* Prior history of severe or life-threatening events from any immune-mediated therapy.",
      "* Receiving another anti-cancer therapy. Adjuvant hormonal therapy for resected breast cancer is permitted.",
      "* Receiving systemic corticosteroid therapy or any other form of immunosuppressive therapy within 7 days prior to enrollment.",
      "* Major surgical procedures within 28 days prior to first dose of study treatment.",
      "* Treatment with live virus, including live-attenuated vaccination, within 14 days prior to the first dose of study treatment. Inactive vaccines and live viral non-replicating vaccines within 3 days prior to first dose of study treatment.",
      "",
      "Prior/Concurrent Clinical Study Experience",
      "",
      "• Treatment in an alternative investigational trial within 28 days prior to enrollment.",
      "",
      "Other Exclusions",
      "",
      "* Female participants of childbearing potential unwilling to use protocol specified method of contraception during treatment and for an additional 60 days after the last dose of study treatment.",
      "* Female participants who are breastfeeding or who plan to breastfeed while on study through 60 days after the last dose of study treatment.",
      "* Female participants planning to become pregnant or donate eggs while on study through 60 days after the last dose of study treatment.",
      "* Female participants of childbearing potential with a positive pregnancy test assessed at screening by a highly sensitive serum pregnancy test.",
      "* Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 60 days after the last dose of study treatment.",
      "* Male participants with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 60 days after the last dose of study treatment.",
      "* Male participants unwilling to abstain from donating sperm during treatment and for an additional 60 days after the last dose of study treatment.",
      "* Participant has known sensitivity to any of the products or components to be administered during dosing.",
      "* Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the participant and investigator's knowledge.",
      "* History or evidence of any other clinically significant disorder, condition, or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to participant safety or interfere with the study evaluation, procedures or completion."
    ],
    "exclusion_criteria": [
      "Inclusion Criteria: -Participants are eligible to be included in the study only if all of the following criteria apply:",
      "",
      "* Participant has provided informed consent prior to initiation of any study specific activities/procedures.",
      "* Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years).",
      "* Histologically or cytologically confirmed small-cell lung cancer (SCLC).",
      "* Diagnosed and treated for LS-SCLC with concurrent chemotherapy and radiotherapy.",
      "* Has completed chemoradiotherapy without progression per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1.) (ie, achieved complete response \\[CR\\], partial response \\[PR\\], or stable disease \\[SD\\]).",
      "* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.",
      "* Minimum life expectancy of 12 weeks.",
      "* Adequate organ function.",
      "* Toxicities attributed to concurrent chemoradiotherapy resolved to grade ≤ 1, unless otherwise specified. Excluding alopecia or fatigue.",
      "",
      "Exclusion Criteria: -Participants are excluded from the study if any of the following criteria apply:",
      "",
      "Disease Related",
      "",
      "* Extensive-stage SCLC (ES-SCLC).",
      "* Any previous diagnosis of transformed non-small-cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) activating mutation positive NSCLC that has transformed to SCLC, or mixed SCLC NSCLC histology.",
      "* Evidence of interstitial lung disease or active, non-infectious pneumonitis. Other Medical Conditions",
      "* History of other malignancy within the past 2 years, with certain exceptions.",
      "* History of solid organ transplantation.",
      "* Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association \\> class II) within 6 months prior to first dose of study treatment.",
      "* History of arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months prior to first dose of study treatment.",
      "* Exclusion of human immunodeficiency virus (HIV) and/or hepatitis infection based on criteria per protocol.",
      "* Participant with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of study treatment.",
      "",
      "Prior/Concomitant Therapy",
      "",
      "* Received sequential chemotherapy and thoracic radiotherapy (no overlap of thoracic radiotherapy with chemotherapy) during chemoradiation.",
      "* Prior therapy with any selective inhibitor of the delta-like ligand 3 (DLL3) pathway.",
      "* Prior history of severe or life-threatening events from any immune-mediated therapy.",
      "* Receiving another anti-cancer therapy. Adjuvant hormonal therapy for resected breast cancer is permitted.",
      "* Receiving systemic corticosteroid therapy or any other form of immunosuppressive therapy within 7 days prior to enrollment.",
      "* Major surgical procedures within 28 days prior to first dose of study treatment.",
      "* Treatment with live virus, including live-attenuated vaccination, within 14 days prior to the first dose of study treatment. Inactive vaccines and live viral non-replicating vaccines within 3 days prior to first dose of study treatment.",
      "",
      "Prior/Concurrent Clinical Study Experience",
      "",
      "• Treatment in an alternative investigational trial within 28 days prior to enrollment.",
      "",
      "Other Exclusions",
      "",
      "* Female participants of childbearing potential unwilling to use protocol specified method of contraception during treatment and for an additional 60 days after the last dose of study treatment.",
      "* Female participants who are breastfeeding or who plan to breastfeed while on study through 60 days after the last dose of study treatment.",
      "* Female participants planning to become pregnant or donate eggs while on study through 60 days after the last dose of study treatment.",
      "* Female participants of childbearing potential with a positive pregnancy test assessed at screening by a highly sensitive serum pregnancy test.",
      "* Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 60 days after the last dose of study treatment.",
      "* Male participants with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 60 days after the last dose of study treatment.",
      "* Male participants unwilling to abstain from donating sperm during treatment and for an additional 60 days after the last dose of study treatment.",
      "* Participant has known sensitivity to any of the products or components to be administered during dosing.",
      "* Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the participant and investigator's knowledge.",
      "* History or evidence of any other clinically significant disorder, condition, or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to participant safety or interfere with the study evaluation, procedures or completion."
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "Not specified",
    "status": "RECRUITING",
    "start_date": "2024-02-20",
    "completion_date": "2029-10-31",
    "sponsor": "Unknown",
    "last_updated": "2025-05-08"
  }
]